BeOne Medicines (ONC) Cash from Investing Activities (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Cash from Investing Activities data on file, last reported at -$45.5 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 62.68% year-over-year to -$45.5 million in Q1 2026; TTM through Mar 2026 was -$199.7 million, a 56.63% increase from a year earlier, with the FY2025 full-year figure at -$276.2 million, up 49.64% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$45.5 million, down from -$38.3 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for ONC reached as high as $658.7 million in Q2 2022 and fell as low as -$209.8 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged $15.7 million across 5 years, with a median of -$49.3 million in 2025.
• Across the five-year window, Cash from Investing Activities jumped 1512.96% in 2022 and sank 263.76% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $38.5 million in 2022, then slumped by 262.4% to -$62.6 million in 2023, then tumbled by 49.57% to -$93.6 million in 2024, then jumped by 59.05% to -$38.3 million in 2025, then dropped by 18.72% to -$45.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$45.5 million in Q1 2026, -$38.3 million in Q4 2025, and -$49.3 million in Q3 2025.